Study Comparing Pembrolizumab/Vibostolimab Combination Therapy to Pembrolizumab Alone for Treating PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Inclusion Criteria

• Diagnosed with Stage IV non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
• Have measurable cancer that can be tracked using standard criteria.
• Not suitable for certain targeted therapies based on specific genetic tests.
• Cancer cells must show PD-L1 expression in at least 1% of cells.
• Be in good overall health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of at least 3 months.
• Female participants must not be pregnant or breastfeeding and must use effective birth control if of childbearing potential.
• Have adequate organ function as determined by medical tests.

Exclusion Criteria

• Have a history of another cancer unless it was treated successfully and has not returned for at least 3 years.
• Have received previous treatments for metastatic NSCLC, except for certain therapies completed at least 6 months before the current diagnosis.
• Have had previous treatments targeting PD-1, PD-L1, or similar pathways.
• Have received radiation therapy within 2 weeks before starting the study treatment.
• Have received a live vaccine within 30 days before starting the study treatment.
• Currently participating in another clinical trial or have used an investigational device recently.
• Have untreated or active cancer spread to the brain or spinal cord.
• Have severe allergies to the study drugs or their ingredients.
• Have an active autoimmune disease requiring treatment in the past 2 years.
• Have a diagnosis of immunodeficiency or are on high-dose steroids or other immunosuppressive treatments.
• Have a history of lung inflammation or current lung disease.
• Have an active infection needing treatment.
• Have a history of HIV, Hepatitis B, or active Hepatitis C.
• Have any condition or treatment that would interfere with the study or is not in the participant's best interest, according to the study doctor.
• Have a psychiatric or substance abuse disorder that would affect participation in the study.